Solésence Announces Uplisting to Nasdaq
Solésence (OTCQB: NANX) has received approval to uplist from OTCQB to the Nasdaq Capital Market, with trading scheduled to begin on Tuesday, April 8, 2025, under the new ticker symbol 'SLSN'. The company, a leader in scientifically-driven health care solutions across beauty and life science categories, met all applicable requirements for Nasdaq listing.
The uplisting process requires no action from current shareholders. CEO Jess Jankowski emphasized that this move is expected to increase visibility within the investment community, broaden the shareholder base, and enhance stakeholder value. COO Kevin Cureton highlighted that this achievement stems from the team's efforts to achieve profitability, successful brand partnerships driving above-industry growth rates, and shareholder support.
Solésence (OTCQB: NANX) ha ricevuto l'approvazione per il passaggio dall'OTCQB al Nasdaq Capital Market, con l'inizio delle negoziazioni previsto per martedì 8 aprile 2025, sotto il nuovo simbolo ticker 'SLSN'. L'azienda, leader nelle soluzioni sanitarie scientificamente orientate nei settori della bellezza e delle scienze della vita, ha soddisfatto tutti i requisiti applicabili per la quotazione al Nasdaq.
Il processo di uplisting non richiede alcuna azione da parte degli attuali azionisti. Il CEO Jess Jankowski ha sottolineato che questa mossa dovrebbe aumentare la visibilità all'interno della comunità degli investitori, ampliare la base degli azionisti e migliorare il valore per gli stakeholder. Il COO Kevin Cureton ha evidenziato che questo traguardo deriva dagli sforzi del team per raggiungere la redditività, dalle partnership di marca di successo che generano tassi di crescita superiori alla media del settore e dal supporto degli azionisti.
Solésence (OTCQB: NANX) ha recibido la aprobación para pasar de OTCQB al Nasdaq Capital Market, con el inicio de las operaciones programado para el martes 8 de abril de 2025, bajo el nuevo símbolo de cotización 'SLSN'. La empresa, líder en soluciones de atención médica impulsadas científicamente en las categorías de belleza y ciencias de la vida, cumplió con todos los requisitos aplicables para la cotización en Nasdaq.
El proceso de uplisting no requiere ninguna acción por parte de los accionistas actuales. El CEO Jess Jankowski enfatizó que este movimiento se espera que aumente la visibilidad dentro de la comunidad inversora, amplíe la base de accionistas y mejore el valor para los interesados. El COO Kevin Cureton destacó que este logro proviene de los esfuerzos del equipo para alcanzar la rentabilidad, de las asociaciones de marca exitosas que impulsan tasas de crecimiento superiores a la media de la industria y del apoyo de los accionistas.
Solésence (OTCQB: NANX)는 OTCQB에서 Nasdaq Capital Market으로의 상장 승인을 받았으며, 2025년 4월 8일 화요일부터 새로운 티커 심볼 'SLSN' 아래에서 거래가 시작될 예정입니다. 이 회사는 미용 및 생명 과학 분야에서 과학 기반의 건강 관리 솔루션을 제공하는 선두 주자로, Nasdaq 상장에 필요한 모든 요건을 충족했습니다.
상장 절차는 현재 주주로부터 아무런 조치를 요구하지 않습니다. CEO인 Jess Jankowski는 이번 결정이 투자 커뮤니티 내에서 가시성을 높이고, 주주 기반을 확대하며, 이해관계자 가치를 향상시킬 것으로 기대된다고 강조했습니다. COO인 Kevin Cureton은 이 성취가 수익성을 달성하기 위한 팀의 노력과 업계 평균을 초과하는 성장률을 이끄는 성공적인 브랜드 파트너십, 그리고 주주 지원에서 비롯된 것이라고 강조했습니다.
Solésence (OTCQB: NANX) a reçu l'approbation pour passer de l'OTCQB au Nasdaq Capital Market, avec un début de négociation prévu pour le mardi 8 avril 2025, sous le nouveau symbole boursier 'SLSN'. L'entreprise, leader dans les solutions de santé basées sur la science dans les domaines de la beauté et des sciences de la vie, a satisfait à toutes les exigences applicables pour la cotation au Nasdaq.
Le processus de passage ne nécessite aucune action de la part des actionnaires actuels. Le PDG Jess Jankowski a souligné que ce mouvement devrait accroître la visibilité au sein de la communauté des investisseurs, élargir la base des actionnaires et améliorer la valeur pour les parties prenantes. Le COO Kevin Cureton a souligné que cette réalisation découle des efforts de l'équipe pour atteindre la rentabilité, des partenariats de marque réussis générant des taux de croissance supérieurs à la moyenne du secteur, et du soutien des actionnaires.
Solésence (OTCQB: NANX) hat die Genehmigung erhalten, von OTCQB zum Nasdaq Capital Market aufzusteigen, wobei der Handel voraussichtlich am Dienstag, den 8. April 2025, unter dem neuen Tickersymbol 'SLSN' beginnen wird. Das Unternehmen, ein führender Anbieter von wissenschaftlich fundierten Gesundheitslösungen in den Bereichen Schönheit und Lebenswissenschaften, hat alle anwendbaren Anforderungen für die Nasdaq-Notierung erfüllt.
Der Uplisting-Prozess erfordert keine Maßnahmen von den aktuellen Aktionären. CEO Jess Jankowski betonte, dass dieser Schritt voraussichtlich die Sichtbarkeit innerhalb der Investmentgemeinschaft erhöhen, die Aktionärsbasis erweitern und den Wert für die Stakeholder steigern wird. COO Kevin Cureton hob hervor, dass dieser Erfolg aus den Bemühungen des Teams resultiert, Rentabilität zu erreichen, erfolgreichen Markenpartnerschaften, die Wachstumsraten über dem Branchendurchschnitt erzielen, und der Unterstützung der Aktionäre.
- Uplisting to Nasdaq Capital Market indicates company meets higher listing standards
- Company reports profitable operations
- Growth rate exceeds industry average according to management
- None.
Trading set to begin Tuesday, April 8 under new ticker “SLSN”
ROMEOVILLE, Ill., April 07, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has received approval from the Listing Qualifications Department of Nasdaq to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be uplisted to Nasdaq at the opening of business on Tuesday, April 8, 2025. Prior to listing on Nasdaq, the Company’s shares traded on the OTCQB. Shareholders are not required to take any action as a result of the uplisting.
The Company’s shares will now trade under the ticker symbol “SLSN”. The approval by Nasdaq was based on the Company meeting all applicable requirements for public listing on the Nasdaq Capital Market.
“We are pleased to announce our uplisting to Nasdaq,” said Jess Jankowski, President and Chief Executive Officer of Solésence. “Solésence continues to redefine mineral-based sun protection as beauty brands recognize the novel skin health benefits from our award-winning products. We believe that trading on Nasdaq will increase our visibility within the investment community, broaden our shareholder base, and deliver greater value to our stakeholders. We look forward to this exciting new chapter in our company’s history."
“This milestone was achieved through our team’s relentless efforts to profitably achieve our mission, our brand partners’ collaboration in driving growth at a multiple of the industry’s growth rate, and the patience and resilience of our shareholders. We’re particularly excited about how Solésence’s uplisting to Nasdaq may one day provide resources to enable our company to scale and increase profitability in a manner not available to most of our competitors,” said Kevin Cureton, Chief Operating Officer.
About Solésence, Inc.
Solésence, Inc., is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.
Forward-Looking Statements
This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2025. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
Media Contact:
media@solesence.com
Investor Relations Contact:
investors@solesence.com
FAQ
When will Solésence (NANX) begin trading on Nasdaq?
What is Solésence's new ticker symbol after uplisting to Nasdaq?
Do Solésence shareholders need to take any action due to the Nasdaq uplisting?
What are the expected benefits of Solésence's uplisting to Nasdaq?
